How many insider trades does FilingIQ track for PRME?

FilingIQ tracks 100 Form 4 insider transactions for PRME (Prime Medicine, Inc.), covering filings from Oct 24, 2022 onwards. 3 of those were filed in the last 90 days.

Are PRME insiders net buyers or net sellers?

Across the full Form 4 history for PRME, 20 transactions (20%) were open-market purchases and 33 (33%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does PRME insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is PRME in?

Prime Medicine, Inc. (PRME) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $691.36M.

PRME insider trading

NasdaqGM Healthcare

Prime Medicine, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

100

Last 90 days

Buys / sells

20% / 33%

Market cap

$691.36M

About Prime Medicine, Inc.

Prime Medicine, Inc., a biotechnology company, engages in delivering genetic therapies to address the spectrum of diseases by deploying gene editing technology in the United States. It offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stranded break in the DNA, as well as a RT domain that copies the edited DNA sequence directly into the target genomic site where the edit is made; and pegRNA which contains a search sequence, also known as a spacer, which provides a target genomic address for the Prime Editor. The company has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. Prime Medicine, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.

Company website: primemedicine.com

PRME insider activity at a glance

FilingIQ has scored 100 insider transactions for PRME since Oct 24, 2022. The most recent filing in our index is dated Feb 26, 2026.

Across the full history, 20 open-market purchases and 33 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on PRME insider trades is 51.4/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live PRME trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

13F funds holding PRME

Samsara BioCapital, LLC

$5.78M · 1.2% of AUM

Frequently asked

How many insider trades does FilingIQ track for PRME?: FilingIQ tracks 100 Form 4 insider transactions for PRME (Prime Medicine, Inc.), covering filings from Oct 24, 2022 onwards. 3 of those were filed in the last 90 days.
Are PRME insiders net buyers or net sellers?: Across the full Form 4 history for PRME, 20 transactions (20%) were open-market purchases and 33 (33%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does PRME insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is PRME in?: Prime Medicine, Inc. (PRME) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $691.36M.

Methodology & sources

Every PRME insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.